Mirati Therapeutics (MRTI) PT Lowered to $193 at Jefferies After 2Q Expenses Were Elevated Ahead of KRAS NDA
Tweet Send to a Friend
Jefferies analyst Maury Raycroft lowered the price target on Mirati Therapeutics Inc.(OTC: MRTI) to $193.00 (from $196.00) on higher expenses ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
